• Corpus ID: 239016805

Sample size calculations for n-of-1 trials

  title={Sample size calculations for n-of-1 trials},
  author={Jiabei Yang and Jon Arni Steingrimsson and Christopher H. Schmid},
N-of-1 trials, single participant trials in which multiple treatments are sequentially randomized over the study period, can give direct estimates of individual-specific treatment effects. Combining nof-1 trials gives extra information for estimating the population average treatment effect compared with randomized controlled trials and increases precision for individual-specific treatment effect estimates. In this paper, we present a procedure for designing n-of-1 trials. We formally define the… 

Figures and Tables from this paper


Individual (N-of-1) trials can be combined to give population comparative treatment effect estimates: methodologic considerations.
Optimal models for combining N-of-1 trials need to consider goals, data sources, and relative within- and between-patient variances and Bayesian hierarchical models improved precision and were highly sensitive to within-patient variance priors.
Statistical power in single subject trials.
A controlled single subject trial compares the efficacy of a new treatment with a control treatment in an individual patient and may improve the certainty of therapeutic decisions in the individual patient.
Sample size considerations for n-of-1 trials
  • S. Senn
  • Mathematics, Medicine
    Statistical methods in medical research
  • 2019
Five different criteria for planning sample sizes for n-of-1 trials are identified, and formulae and advice to address the associated tasks are provided.
Single-patient (n-of-1) trials: a pragmatic clinical decision methodology for patient-centered comparative effectiveness research.
Single-patient trials may be poised to emerge as an important part of the methodological armamentarium for comparative effectiveness research and patient-centered outcomes research.
One-stage individual participant data meta-analysis models for continuous and binary outcomes: Comparison of treatment coding options and estimation methods.
Simulation is used to evaluate the performance of restricted maximum likelihood (REML) andmaximum likelihood (ML) estimation of one-stage IPD meta-analysis models for synthesizing randomized trials with continuous or binary outcomes.
Heterogeneity of treatment effects: implications for guidelines, payment, and quality assessment.
Sources of heterogeneity of treatment effects (HTE) within trials are described, which can compromise the interpretation and generalizability of results and are examined in practice to increase the usefulness of trial results.
Individual participant data meta‐analysis of continuous outcomes: A comparison of approaches for specifying and estimating one‐stage models
The findings reveal that, for an individual participant data meta‐analysis of randomized trials with a 1:1 treatment:control allocation ratio and heterogeneity in the treatment effect, bias and coverage of the summary treatment effect estimate are very similar when using stratified or random intercept models with restricted maximum likelihood.
A comparison of seven random‐effects models for meta‐analyses that estimate the summary odds ratio
It is concluded that generalised linear mixed models can result in better statistical inference than the conventional 2‐stage approach but also that this type of model presents issues and difficulties.
Random-effects models for longitudinal data.
A unified approach to fitting these models, based on a combination of empirical Bayes and maximum likelihood estimation of model parameters and using the EM algorithm, is discussed.
The PREEMPT study - evaluating smartphone-assisted n-of-1 trials in patients with chronic pain: study protocol for a randomized controlled trial
The goal of the PREEMPT study is to test the ‘Trialist’ mobile health smartphone app, which has been developed to make n-of-1 trials easier to accomplish, and to provide patients and clinicians with tools for individualizing treatments for chronic pain.